Ingmar Bruns serves as Chief Medical Officer at Zentalis Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Ingmar Bruns has executed 3 insider transactions totaling $8.0K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 9, 2026 involved selling 335 shares valued at $802.
Ingmar Bruns currently holds 33,332 shares of Zentalis Pharmaceuticals, Inc. (ZNTL), valued at approximately $0. This represents their equity stake as Chief Medical Officer.
Based on SEC Form 4 filings, Ingmar Bruns has been a net seller of ZNTL stock. They have purchased $0 and sold $8.0K worth of shares.
Ingmar Bruns's most recent insider trade was on Feb 9, 2026, when they sold 335 shares at $2.39 per share.
Get notified when new Form 4 filings are submitted
| $2.43 |
| Discretionary |
| Jan 8, 2026 | ZNTL | $0 | Award | 365,000 | $N/A | Discretionary |